(Q36346370)

13 August 2017

1 reference

title

Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies (English)

1 reference

chronic lymphocytic leukemia

13 August 2017

0 references

1 reference

1 reference

1

Tadeusz Robak

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

22

1 reference

13 August 2017

issue

12

1 reference

13 August 2017

page(s)

983-1012

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200522120-00002

13 August 2017

exact match

0 references

cites work

2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200522120-00002

Deoxycoformycin in the treatment of mature B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200522120-00002

Infectious complications of purine analog therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200522120-00002

Management of the Chronic Leukemias: Special Considerations in the Elderly Patient. Part I. Chronic Lymphocytic Leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200522120-00002

2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200522120-00002

Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia

21 January 2018

1 reference

12 December 2020

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

12 December 2020

The bioavailability of oral fludarabine phosphate is unaffected by food

1 reference

12 December 2020

Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia

1 reference

12 December 2020

In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features

1 reference

12 December 2020

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

1 reference

12 December 2020

Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

In vivo 'Purging' of residual disease in CLL with Campath-1H

1 reference

12 December 2020

Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

1 reference

12 December 2020

High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized tria

1 reference

12 December 2020

Richter syndrome: biology, incidence, and therapeutic strategies

1 reference

12 December 2020

Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies

1 reference

12 December 2020

Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia

1 reference

12 December 2020

Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia

1 reference

12 December 2020

Pure red cell aplasia in patients with chronic lymphocytic leukaemia treated with cladribine

1 reference

12 December 2020

Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent

1 reference

12 December 2020

Application of population pharmacokinetics to cladribine

1 reference

12 December 2020

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

12 December 2020

Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience

1 reference

12 December 2020

Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab

1 reference

12 December 2020

Chemosensitivity in vitro to 2-chlorodeoxyadenosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in previously unexposed cases of chronic lymphocytic leukemia

1 reference

12 December 2020

Severe immunodeficiency in patients treated with fludarabine monophosphate

1 reference

12 December 2020

Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis

1 reference

12 December 2020

Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance

1 reference

12 December 2020

Prophylactic strategies to meet infectious complications in fludarabine-treated CLL.

1 reference

12 December 2020

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

12 December 2020

Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia

1 reference

12 December 2020

2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia

1 reference

12 December 2020

Mechanism of action of purine analogues in chronic lymphocytic leukaemia

1 reference

12 December 2020

Infectious complications after 2-chlorodeoxyadenosine therapy.

1 reference

12 December 2020

Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.

1 reference

12 December 2020

2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

The role of stem cell transplantation in chronic lymphocytic leukemia

1 reference

12 December 2020

Stem cell transplantation for chronic lymphocytic leukaemia

1 reference

12 December 2020

Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells

1 reference

12 December 2020

Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2'-deoxycoformycin and 2'-deoxyadenosine: association with dATP-dependent activation of caspase-3

1 reference

12 December 2020

Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

12 December 2020

Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

The clinical and epidemiological burden of chronic lymphocytic leukaemia

1 reference

12 December 2020

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

12 December 2020

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

12 December 2020

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

12 December 2020

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia

1 reference

12 December 2020

Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.

1 reference

12 December 2020

Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia

1 reference

12 December 2020

CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas.

1 reference

12 December 2020

Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis

1 reference

12 December 2020

Richter's syndrome: a report on 39 patients

1 reference

12 December 2020

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment

1 reference

12 December 2020

Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia

1 reference

12 December 2020

Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders.

1 reference

12 December 2020

Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine

1 reference

12 December 2020

Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA)

1 reference

12 December 2020

Alemtuzumab in the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

1 reference

12 December 2020

Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy

1 reference

12 December 2020

Non-Hodgkin's lymphoma: the evolving role of purine analogues

1 reference

12 December 2020

Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leuk

1 reference

12 December 2020

The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil.

1 reference

12 December 2020

Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388

1 reference

12 December 2020

Progression and survival studies in early chronic lymphocytic leukemia

1 reference

12 December 2020

Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway

1 reference

12 December 2020

Purine nucleoside analogues in the treatment of myleoid leukemias

1 reference

12 December 2020

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

1 reference

12 December 2020

Infectious and immunosuppressive complications of purine analog therapy.

1 reference

12 December 2020

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response

1 reference

12 December 2020

Treatment of resistant/relapsing chronic lymphocytic leukemia with a combination regimen containing deoxycoformycin and rituximab

1 reference

12 December 2020

Nucleoside transporters in chronic lymphocytic leukaemia

1 reference

12 December 2020

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Treatment of T-cell non-Hodgkin's lymphoma.

1 reference

12 December 2020

Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.

1 reference

12 December 2020

Metabolism and action of purine nucleoside analogs

1 reference

12 December 2020

Cladribine (2-chlorodeoxyadenosine)

1 reference

12 December 2020

Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.

1 reference

12 December 2020

In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Infections in patients with chronic lymphocytic leukemia treated with fludarabine

1 reference

12 December 2020

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

12 December 2020

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

12 December 2020

Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients

1 reference

12 December 2020

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

1 reference

12 December 2020

On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration

1 reference

12 December 2020

Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro

1 reference

12 December 2020

Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy

1 reference

12 December 2020

Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro

1 reference

12 December 2020

The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia

1 reference

12 December 2020

Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388

1 reference

12 December 2020

Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias

1 reference

12 December 2020

Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation

1 reference

12 December 2020

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

12 December 2020

Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine

1 reference

12 December 2020

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

1 reference

12 December 2020

Natural history of stage A chronic lymphocytic leukaemia untreated patients. French Cooperative Group on Chronic Lymphocytic Leukaemia

1 reference

12 December 2020

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

1 reference

12 December 2020

Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria

1 reference

12 December 2020

On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans

1 reference

12 December 2020

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

12 December 2020

Towards the pharmacotherapy of hairy cell leukaemia

1 reference

12 December 2020

Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

12 December 2020

Management of chronic lymphocytic leukaemia

1 reference

12 December 2020

2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.

1 reference

12 December 2020

Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.

1 reference

12 December 2020

Pure red-cell aplasia with fludarabine for chronic lymphocytic leukaemia

1 reference

12 December 2020

Waldenström's macroglobulinaemia

1 reference

12 December 2020

Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment.

1 reference

12 December 2020

Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo

1 reference

12 December 2020

Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia

1 reference

12 December 2020

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.

1 reference

12 December 2020

Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia

1 reference

12 December 2020

Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine

1 reference

12 December 2020

Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment

1 reference

12 December 2020

Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.

1 reference

12 December 2020

Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2'-deoxyadenosine

1 reference

12 December 2020

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

1 reference

12 December 2020

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

1 reference

12 December 2020

In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia

1 reference

12 December 2020

Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival

1 reference

12 December 2020

Cladribine in the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

Cellular and clinical pharmacology of fludarabine

1 reference

12 December 2020

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

1 reference

12 December 2020

Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway

1 reference

12 December 2020

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

1 reference

12 December 2020

Chronic lymphocytic leukemia in (Richter's) transformation.

1 reference

12 December 2020

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

1 reference

12 December 2020

Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2'-deoxyadenosine

1 reference

12 December 2020

Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis

1 reference

12 December 2020

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

1 reference

12 December 2020

Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.

1 reference

12 December 2020

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

1 reference

12 December 2020

Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.

1 reference

12 December 2020

When and how to treat chronic lymphocytic leukemia

1 reference

12 December 2020

Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: A report of 12 patients from a single institution

1 reference

12 December 2020

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

1 reference

12 December 2020

P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia

1 reference

12 December 2020

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

12 December 2020

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

12 December 2020

Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair.

1 reference

12 December 2020

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

1 reference

12 December 2020

First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease

1 reference

12 December 2020

Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy

1 reference

12 December 2020

Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy

1 reference

12 December 2020

Detection of minimal residual disease in B Chronic Lymphocytic Leukemia (CLL)

1 reference

12 December 2020

Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).

1 reference

12 December 2020

10.2165/00002512-200522120-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

1008465404

0 references

1 reference